JP6073382B2 - 癌のレベルの区分に対するdna断片のサイズに基づく解析 - Google Patents
癌のレベルの区分に対するdna断片のサイズに基づく解析 Download PDFInfo
- Publication number
- JP6073382B2 JP6073382B2 JP2014560451A JP2014560451A JP6073382B2 JP 6073382 B2 JP6073382 B2 JP 6073382B2 JP 2014560451 A JP2014560451 A JP 2014560451A JP 2014560451 A JP2014560451 A JP 2014560451A JP 6073382 B2 JP6073382 B2 JP 6073382B2
- Authority
- JP
- Japan
- Prior art keywords
- size
- dna
- value
- cancer
- fractional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012634 fragment Substances 0.000 title claims description 184
- 206010028980 Neoplasm Diseases 0.000 title claims description 146
- 201000011510 cancer Diseases 0.000 title claims description 58
- 238000004458 analytical method Methods 0.000 title description 20
- 239000000523 sample Substances 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 66
- 239000012472 biological sample Substances 0.000 claims description 57
- 238000012163 sequencing technique Methods 0.000 claims description 44
- 230000008569 process Effects 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 description 457
- 230000001605 fetal effect Effects 0.000 description 153
- 230000008774 maternal effect Effects 0.000 description 70
- 238000002271 resection Methods 0.000 description 34
- 238000009826 distribution Methods 0.000 description 33
- 238000001962 electrophoresis Methods 0.000 description 33
- 230000006870 function Effects 0.000 description 33
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 30
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 30
- 230000000875 corresponding effect Effects 0.000 description 22
- 210000003754 fetus Anatomy 0.000 description 17
- 238000005259 measurement Methods 0.000 description 14
- 230000002759 chromosomal effect Effects 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 230000007423 decrease Effects 0.000 description 11
- 210000000349 chromosome Anatomy 0.000 description 10
- 210000002593 Y chromosome Anatomy 0.000 description 9
- 208000036878 aneuploidy Diseases 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 201000010374 Down Syndrome Diseases 0.000 description 8
- 230000003394 haemopoietic effect Effects 0.000 description 8
- 230000003252 repetitive effect Effects 0.000 description 8
- 230000003321 amplification Effects 0.000 description 7
- 238000011088 calibration curve Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 201000006360 Edwards syndrome Diseases 0.000 description 6
- 201000009928 Patau syndrome Diseases 0.000 description 6
- 206010044686 Trisomy 13 Diseases 0.000 description 6
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 6
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 6
- 206010044688 Trisomy 21 Diseases 0.000 description 6
- 238000012886 linear function Methods 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 206010053884 trisomy 18 Diseases 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 108091023043 Alu Element Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 230000007067 DNA methylation Effects 0.000 description 5
- 231100001075 aneuploidy Toxicity 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 4
- 230000003322 aneuploid effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 230000008775 paternal effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 238000003793 prenatal diagnosis Methods 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 108091092240 circulating cell-free DNA Proteins 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001973 epigenetic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 101150108975 Rhd gene Proteins 0.000 description 1
- 101710179516 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Proteins 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000012774 diagnostic algorithm Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- General Physics & Mathematics (AREA)
- Mathematical Optimization (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608623P | 2012-03-08 | 2012-03-08 | |
| US61/608,623 | 2012-03-08 | ||
| US201261621451P | 2012-04-06 | 2012-04-06 | |
| US61/621,451 | 2012-04-06 | ||
| PCT/IB2013/000312 WO2013132305A1 (en) | 2012-03-08 | 2013-03-08 | Size-based analysis of fetal dna fraction in maternal plasma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000134A Division JP6392904B2 (ja) | 2012-03-08 | 2017-01-04 | Dnaのサイズに基づく解析 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510757A JP2015510757A (ja) | 2015-04-13 |
| JP2015510757A5 JP2015510757A5 (enExample) | 2015-05-21 |
| JP6073382B2 true JP6073382B2 (ja) | 2017-02-01 |
Family
ID=49114635
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560451A Active JP6073382B2 (ja) | 2012-03-08 | 2013-03-08 | 癌のレベルの区分に対するdna断片のサイズに基づく解析 |
| JP2017000134A Active JP6392904B2 (ja) | 2012-03-08 | 2017-01-04 | Dnaのサイズに基づく解析 |
| JP2018156137A Active JP6721642B2 (ja) | 2012-03-08 | 2018-08-23 | Dnaのサイズに基づく解析 |
| JP2020105483A Active JP6849257B2 (ja) | 2012-03-08 | 2020-06-18 | Dnaのサイズに基づく解析 |
| JP2021028536A Active JP7197209B2 (ja) | 2012-03-08 | 2021-02-25 | Dnaのサイズに基づく解析 |
| JP2022196192A Pending JP2023017006A (ja) | 2012-03-08 | 2022-12-08 | Dnaのサイズに基づく解析 |
| JP2024083480A Pending JP2024100931A (ja) | 2012-03-08 | 2024-05-22 | Dnaのサイズに基づく解析 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000134A Active JP6392904B2 (ja) | 2012-03-08 | 2017-01-04 | Dnaのサイズに基づく解析 |
| JP2018156137A Active JP6721642B2 (ja) | 2012-03-08 | 2018-08-23 | Dnaのサイズに基づく解析 |
| JP2020105483A Active JP6849257B2 (ja) | 2012-03-08 | 2020-06-18 | Dnaのサイズに基づく解析 |
| JP2021028536A Active JP7197209B2 (ja) | 2012-03-08 | 2021-02-25 | Dnaのサイズに基づく解析 |
| JP2022196192A Pending JP2023017006A (ja) | 2012-03-08 | 2022-12-08 | Dnaのサイズに基づく解析 |
| JP2024083480A Pending JP2024100931A (ja) | 2012-03-08 | 2024-05-22 | Dnaのサイズに基づく解析 |
Country Status (18)
| Country | Link |
|---|---|
| US (7) | US9892230B2 (enExample) |
| EP (10) | EP3617324B1 (enExample) |
| JP (7) | JP6073382B2 (enExample) |
| CN (3) | CN107630070B (enExample) |
| AU (4) | AU2013229186B2 (enExample) |
| CA (2) | CA2865523C (enExample) |
| CY (1) | CY1121828T1 (enExample) |
| DK (5) | DK2860266T3 (enExample) |
| ES (3) | ES2729504T3 (enExample) |
| HR (1) | HRP20191300T1 (enExample) |
| HU (1) | HUE044746T2 (enExample) |
| LT (1) | LT3301193T (enExample) |
| PL (1) | PL3301193T3 (enExample) |
| PT (1) | PT3301193T (enExample) |
| RS (1) | RS59073B1 (enExample) |
| SI (1) | SI3301193T1 (enExample) |
| SM (1) | SMT201900409T1 (enExample) |
| WO (1) | WO2013132305A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023017006A (ja) * | 2012-03-08 | 2023-02-02 | ザ チャイニーズ ユニバーシティー オブ ホンコン | Dnaのサイズに基づく解析 |
Families Citing this family (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11111543B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| CN101153336B (zh) | 2006-09-27 | 2011-09-07 | 香港中文大学 | 检测dna甲基化程度的方法和试剂盒 |
| EP2496713B1 (en) | 2009-11-06 | 2018-07-18 | The Chinese University of Hong Kong | Size-based genomic analysis |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11322224B2 (en) * | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| JP6153874B2 (ja) | 2011-02-09 | 2017-06-28 | ナテラ, インコーポレイテッド | 非侵襲的出生前倍数性呼び出しのための方法 |
| WO2012177792A2 (en) | 2011-06-24 | 2012-12-27 | Sequenom, Inc. | Methods and processes for non-invasive assessment of a genetic variation |
| US9367663B2 (en) | 2011-10-06 | 2016-06-14 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10424394B2 (en) | 2011-10-06 | 2019-09-24 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2850785C (en) | 2011-10-06 | 2022-12-13 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9984198B2 (en) | 2011-10-06 | 2018-05-29 | Sequenom, Inc. | Reducing sequence read count error in assessment of complex genetic variations |
| US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| AU2013209499B2 (en) | 2012-01-20 | 2018-05-10 | Sequenom, Inc. | Diagnostic processes that factor experimental conditions |
| US9605313B2 (en) | 2012-03-02 | 2017-03-28 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US10504613B2 (en) | 2012-12-20 | 2019-12-10 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3978621B1 (en) * | 2012-05-21 | 2023-08-30 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9920361B2 (en) | 2012-05-21 | 2018-03-20 | Sequenom, Inc. | Methods and compositions for analyzing nucleic acid |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| US10497461B2 (en) | 2012-06-22 | 2019-12-03 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| CN110872617A (zh) | 2012-09-04 | 2020-03-10 | 夸登特健康公司 | 检测稀有突变和拷贝数变异的系统和方法 |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10482994B2 (en) | 2012-10-04 | 2019-11-19 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP4293125A3 (en) | 2012-12-10 | 2024-02-28 | Resolution Bioscience, Inc. | Methods for targeted genomic analysis |
| US20130309666A1 (en) | 2013-01-25 | 2013-11-21 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2014168711A1 (en) | 2013-03-13 | 2014-10-16 | Sequenom, Inc. | Primers for dna methylation analysis |
| LT2981921T (lt) | 2013-04-03 | 2023-02-27 | Sequenom, Inc. | Neinvazinio genetinių variacijų vertinimo būdai ir procesai |
| AU2014268377B2 (en) | 2013-05-24 | 2020-10-08 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| LT3011051T (lt) | 2013-06-21 | 2019-05-10 | Sequenom, Inc. | Genetinių variacijų neinvazinis vertinimo būdas |
| US10174375B2 (en) * | 2013-09-20 | 2019-01-08 | The Chinese University Of Hong Kong | Sequencing analysis of circulating DNA to detect and monitor autoimmune diseases |
| PL3053071T3 (pl) | 2013-10-04 | 2024-03-18 | Sequenom, Inc. | Metody i procesy nieinwazyjnej oceny zmienności genetycznych |
| AU2014332241B2 (en) | 2013-10-07 | 2021-04-29 | Sequenom, Inc. | Methods and processes for non-invasive assessment of chromosome alterations |
| EP4227947A1 (en) | 2013-10-21 | 2023-08-16 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
| KR20240038168A (ko) | 2013-11-07 | 2024-03-22 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 인간 마이크로바이옴 및 그의 성분의 분석을 위한 무세포 핵산 |
| GB2520765A (en) * | 2013-12-02 | 2015-06-03 | Vanadis Diagnostics Ab | Multiplex detection of nucleic acids |
| CN111534580B (zh) | 2013-12-28 | 2024-06-04 | 夸登特健康公司 | 用于检测遗传变异的方法和系统 |
| GB2524948A (en) * | 2014-03-07 | 2015-10-14 | Oxford Gene Technology Operations Ltd | Detecting Increase or Decrease in the Amount of a Nucleic Acid having a Sequence of Interest |
| EP3736344A1 (en) | 2014-03-13 | 2020-11-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CN109971852A (zh) | 2014-04-21 | 2019-07-05 | 纳特拉公司 | 检测染色体片段中的突变和倍性 |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| EP2942400A1 (en) | 2014-05-09 | 2015-11-11 | Lifecodexx AG | Multiplex detection of DNA that originates from a specific cell-type |
| SG11201608993RA (en) | 2014-05-09 | 2016-11-29 | Lifecodexx Ag | Detection of dna that originates from a specific cell-type and related methods |
| BR112016027848A2 (pt) | 2014-05-30 | 2017-08-22 | Verinata Health Inc | Método para avaliação de número de cópias de uma sequência de interesse, meio legível por máquina não transitória, e, sistema para avaliação de número de cópias de uma sequência de interesse |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| CN107002122B (zh) | 2014-07-25 | 2023-09-19 | 华盛顿大学 | 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法 |
| ES2903103T3 (es) * | 2014-07-25 | 2022-03-31 | Bgi Genomics Co Ltd | Método para determinar la fracción de ácidos nucleicos fetales libres de células en una muestra de sangre periférica de una mujer embarazada y uso del mismo |
| US11783911B2 (en) * | 2014-07-30 | 2023-10-10 | Sequenom, Inc | Methods and processes for non-invasive assessment of genetic variations |
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| MA40939A (fr) | 2014-12-12 | 2017-10-18 | Verinata Health Inc | Utilisation de la taille de fragments d'adn acellulaire pour déterminer les variations du nombre de copies |
| US11242559B2 (en) | 2015-01-13 | 2022-02-08 | The Chinese University Of Hong Kong | Method of nuclear DNA and mitochondrial DNA analysis |
| US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
| US10319463B2 (en) * | 2015-01-23 | 2019-06-11 | The Chinese University Of Hong Kong | Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations |
| EP4012715B1 (en) | 2015-02-10 | 2025-09-24 | The Chinese University Of Hong Kong | Detecting mutations for cancer screening and fetal analysis |
| CN104789686B (zh) * | 2015-05-06 | 2018-09-07 | 浙江安诺优达生物科技有限公司 | 检测染色体非整倍性的试剂盒和装置 |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| US11111520B2 (en) | 2015-05-18 | 2021-09-07 | Karius, Inc. | Compositions and methods for enriching populations of nucleic acids |
| EP3666902B1 (en) | 2015-05-22 | 2024-07-03 | Medicover Public Co Ltd | Multiplexed parallel analysis of targeted genomic regions for non-invasive prenatal testing |
| FI3967775T3 (fi) | 2015-07-23 | 2023-09-25 | Univ Hong Kong Chinese | Soluttoman DNA:n fragmentointimallien analyysi |
| ES2891337T3 (es) * | 2015-09-11 | 2022-01-27 | Inst Nat Sante Rech Med | Métodos no invasivos para evaluar la integridad genética de células troncales pluripotentes |
| SG10202107693TA (en) | 2015-09-22 | 2021-09-29 | Univ Hong Kong Chinese | Accurate quantification of fetal dna fraction by shallow-depth sequencing of maternal plasma dna |
| KR101848438B1 (ko) * | 2015-10-29 | 2018-04-13 | 바이오코아 주식회사 | 디지털 pcr을 이용한 산전진단 방법 |
| EP3168309B8 (en) | 2015-11-10 | 2020-06-03 | Eurofins LifeCodexx GmbH | Detection of foetal chromosomal aneuploidies using dna regions that are differentially methylated between the foetus and the pregnant female |
| MX2018005858A (es) | 2015-11-11 | 2019-02-20 | Resolution Bioscience Inc | Construccion de alta eficacia de bibliotecas de adn. |
| WO2017106768A1 (en) | 2015-12-17 | 2017-06-22 | Guardant Health, Inc. | Methods to determine tumor gene copy number by analysis of cell-free dna |
| US10095831B2 (en) | 2016-02-03 | 2018-10-09 | Verinata Health, Inc. | Using cell-free DNA fragment size to determine copy number variations |
| WO2017165852A1 (en) | 2016-03-24 | 2017-09-28 | Biological Dynamics, Inc. | Disposable fluidic cartridge and components |
| US9976181B2 (en) | 2016-03-25 | 2018-05-22 | Karius, Inc. | Synthetic nucleic acid spike-ins |
| CA3016360A1 (en) | 2016-04-15 | 2017-10-19 | Ucl Business Plc | Methods for lung cancer detection |
| CA3030890A1 (en) | 2016-07-27 | 2018-02-01 | Sequenom, Inc. | Genetic copy number alteration classifications |
| WO2018039463A1 (en) | 2016-08-25 | 2018-03-01 | Resolution Bioscience, Inc. | Methods for the detection of genomic copy changes in dna samples |
| MY205940A (en) | 2016-10-19 | 2024-11-21 | Univ Hong Kong Chinese | Gestational age assessment by methylation and size profiling of maternal plasma dna |
| MY195527A (en) | 2016-10-24 | 2023-01-30 | Grail Inc | Methods And Systems For Tumor Detection |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| CN109906276A (zh) | 2016-11-07 | 2019-06-18 | 格里尔公司 | 用于检测早期癌症中体细胞突变特征的识别方法 |
| IL266347B2 (en) | 2016-11-30 | 2025-01-01 | Univ Hong Kong Chinese | Analysis of cell-free DNA in urine and other samples |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| CN106591451B (zh) * | 2016-12-14 | 2020-06-23 | 北京贝瑞和康生物技术有限公司 | 测定胎儿游离dna含量的方法及其用于实施该方法的装置 |
| WO2018140521A1 (en) | 2017-01-24 | 2018-08-02 | Sequenom, Inc. | Methods and processes for assessment of genetic variations |
| US10633713B2 (en) | 2017-01-25 | 2020-04-28 | The Chinese University Of Hong Kong | Diagnostic applications using nucleic acid fragments |
| WO2018170511A1 (en) | 2017-03-17 | 2018-09-20 | Sequenom, Inc. | Methods and processes for assessment of genetic mosaicism |
| US10697008B2 (en) | 2017-04-12 | 2020-06-30 | Karius, Inc. | Sample preparation methods, systems and compositions |
| US11342047B2 (en) | 2017-04-21 | 2022-05-24 | Illumina, Inc. | Using cell-free DNA fragment size to detect tumor-associated variant |
| US10818379B2 (en) | 2017-05-08 | 2020-10-27 | Biological Dynamics, Inc. | Methods and systems for analyte information processing |
| CN111051536A (zh) | 2017-07-26 | 2020-04-21 | 香港中文大学 | 利用不含细胞的病毒核酸改善癌症筛选 |
| AU2018355575A1 (en) | 2017-10-27 | 2020-05-21 | Juno Diagnostics, Inc. | Devices, systems and methods for ultra-low volume liquid biopsy |
| US11168356B2 (en) | 2017-11-02 | 2021-11-09 | The Chinese University Of Hong Kong | Using nucleic acid size range for noninvasive cancer detection |
| WO2019118926A1 (en) | 2017-12-14 | 2019-06-20 | Tai Diagnostics, Inc. | Assessing graft suitability for transplantation |
| WO2019126391A1 (en) * | 2017-12-19 | 2019-06-27 | Biological Dynamics, Inc. | Methods and devices for detecting and quantifying cell-free dna fragments |
| CN116121340A (zh) | 2017-12-19 | 2023-05-16 | 生物动力学公司 | 用于从生物样品中检测多种分析物的方法和装置 |
| US12398389B2 (en) | 2018-02-15 | 2025-08-26 | Natera, Inc. | Methods for isolating nucleic acids with size selection |
| JP2021518106A (ja) * | 2018-03-13 | 2021-08-02 | ガーダント ヘルス, インコーポレイテッド | 治療用核酸構築物の非侵襲的な検出およびモニタリングのための方法 |
| EP3765592A4 (en) | 2018-03-16 | 2021-12-08 | Karius Inc. | SAMPLE SERIES TO DIFFERENTIATE TARGET NUCLEIC ACIDS FROM CONTAMINANT NUCLEIC ACIDS |
| CA3095030A1 (en) | 2018-03-30 | 2019-10-03 | Juno Diagnostics, Inc. | Deep learning-based methods, devices, and systems for prenatal testing |
| CN117065932A (zh) | 2018-04-02 | 2023-11-17 | 生物动力学公司 | 介电材料 |
| AU2019249422B2 (en) | 2018-04-02 | 2025-09-25 | GRAIL, Inc | Methylation markers and targeted methylation probe panels |
| WO2019200228A1 (en) | 2018-04-14 | 2019-10-17 | Natera, Inc. | Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna |
| WO2019209884A1 (en) | 2018-04-23 | 2019-10-31 | Grail, Inc. | Methods and systems for screening for conditions |
| WO2019226822A1 (en) * | 2018-05-23 | 2019-11-28 | The Regents Of The University Of California | Methods of analyzing capped ribonucleic acids |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| EP3856903A4 (en) | 2018-09-27 | 2022-07-27 | Grail, LLC | METHYLATION MARKER AND TARGETED METHYLATION PROBE PANEL |
| UY38479A (es) | 2018-11-19 | 2020-06-30 | Sist Genomicos S L | Método y producto informático de análisis de adn fetal por secuenciación masiva |
| CA3118990A1 (en) | 2018-11-21 | 2020-05-28 | Karius, Inc. | Direct-to-library methods, systems, and compositions |
| TW202536188A (zh) * | 2018-12-19 | 2025-09-16 | 香港中文大學 | 游離dna末端特徵 |
| WO2020186024A1 (en) | 2019-03-13 | 2020-09-17 | Grail, Inc. | Systems and methods for enriching for cancer-derived fragments using fragment size |
| TWI874374B (zh) | 2019-03-25 | 2025-03-01 | 香港中文大學 | 確定循環核酸之線性及環狀形式 |
| CN110136794A (zh) * | 2019-05-22 | 2019-08-16 | 湖北可汗广电文化有限公司 | 一种基于人工智能的母婴全生命周期健康医疗服务系统 |
| US20230178182A1 (en) * | 2019-08-19 | 2023-06-08 | Green Cross Genome Corporation | Method for detecting chromosomal abnormality by using information about distance between nucleic acid fragments |
| CN114585749B (zh) * | 2019-10-16 | 2024-09-03 | 斯蒂拉科技公司 | 核酸序列浓度的确定 |
| AU2020391488A1 (en) | 2019-11-27 | 2022-06-09 | GRAIL, Inc | Systems and methods for evaluating longitudinal biological feature data |
| GB2620304B (en) | 2020-02-05 | 2024-06-19 | Univ Hong Kong Chinese | Molecular analyses using long cell-free fragments in pregnancy |
| US11211147B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing |
| US11475981B2 (en) | 2020-02-18 | 2022-10-18 | Tempus Labs, Inc. | Methods and systems for dynamic variant thresholding in a liquid biopsy assay |
| US11211144B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Methods and systems for refining copy number variation in a liquid biopsy assay |
| WO2022271730A1 (en) | 2021-06-21 | 2022-12-29 | Guardant Health, Inc. | Methods and compositions for copy-number informed tissue-of-origin analysis |
| EP4409024A1 (en) | 2021-09-30 | 2024-08-07 | Guardant Health, Inc. | Compositions and methods for synthesis and use of probes targeting nucleic acid rearrangements |
| KR20240174893A (ko) | 2023-06-08 | 2024-12-18 | 지놈케어 주식회사 | 태아 분획을 증가시키는 방법 |
| WO2025137389A2 (en) | 2023-12-22 | 2025-06-26 | Guardant Health, Inc. | Methods for targeted single-molecule genetic and epigenetic sequencing |
Family Cites Families (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6440706B1 (en) | 1999-08-02 | 2002-08-27 | Johns Hopkins University | Digital amplification |
| EP2088209B1 (en) | 1999-10-13 | 2017-05-31 | Sequenom, Inc. | Methods for generating databases for identifying polymorphic genetic markers |
| GB0016742D0 (en) | 2000-07-10 | 2000-08-30 | Simeg Limited | Diagnostic method |
| US6664056B2 (en) | 2000-10-17 | 2003-12-16 | The Chinese University Of Hong Kong | Non-invasive prenatal monitoring |
| US8898021B2 (en) | 2001-02-02 | 2014-11-25 | Mark W. Perlin | Method and system for DNA mixture analysis |
| JP2002272497A (ja) | 2001-03-15 | 2002-09-24 | Venture Link Co Ltd | 癌の診断方法、およびその診断用ベクター |
| KR101002499B1 (ko) | 2001-03-23 | 2010-12-17 | 센텔리옹 에스아에스 | 2본쇄 dna 표적 서열을 3중 나선 상호작용에 의해 정제 및 검출하는 방법 |
| WO2003030823A2 (en) | 2001-10-05 | 2003-04-17 | Combinatorx, Incorporated | Combinations for the treatment of immunoinflammatory disorders |
| US20030180765A1 (en) | 2002-02-01 | 2003-09-25 | The Johns Hopkins University | Digital amplification for detection of mismatch repair deficient tumor cells |
| US6977162B2 (en) | 2002-03-01 | 2005-12-20 | Ravgen, Inc. | Rapid analysis of variations in a genome |
| EP1481097A4 (en) | 2002-03-01 | 2006-08-02 | Ravgen Inc | QUICK ANALYSIS OF VARIATIONS IN A GENOME |
| AU2003262717A1 (en) | 2002-08-15 | 2004-03-03 | Genzyme Corporation | Brain endothelial cell expression patterns |
| US7704687B2 (en) | 2002-11-15 | 2010-04-27 | The Johns Hopkins University | Digital karyotyping |
| CA2517017A1 (en) | 2003-02-28 | 2004-09-16 | Ravgen, Inc. | Methods for detection of genetic disorders |
| WO2004078999A1 (en) | 2003-03-05 | 2004-09-16 | Genetic Technologies Limited | Identification of fetal dna and fetal cell markers in maternal plasma or serum |
| AU2003901671A0 (en) | 2003-04-02 | 2003-05-01 | The University Of Adelaide | Comparative genomic hybridization |
| RU2249820C1 (ru) | 2003-08-18 | 2005-04-10 | Лактионов Павел Петрович | Способ ранней диагностики заболеваний, связанных с нарушением функционирования генетического аппарата клетки |
| US20050282213A1 (en) | 2003-09-22 | 2005-12-22 | Trisogen Biotechnology Limited Partnership | Methods and kits useful for detecting an alteration in a locus copy number |
| CN1930303B (zh) | 2003-10-08 | 2013-11-20 | 波士顿大学信托人 | 染色体异常的产前诊断试剂盒 |
| ATE435301T1 (de) | 2003-10-16 | 2009-07-15 | Sequenom Inc | Nicht invasiver nachweis fötaler genetischer merkmale |
| WO2005039389A2 (en) | 2003-10-22 | 2005-05-06 | 454 Corporation | Sequence-based karyotyping |
| AU2004286845A1 (en) | 2003-10-30 | 2005-05-19 | Tufts-New England Medical Center | Prenatal diagnosis using cell-free fetal DNA in amniotic fluid |
| DE102004036285A1 (de) | 2004-07-27 | 2006-02-16 | Advalytix Ag | Verfahren zum Bestimmen der Häufigkeit von Sequenzen einer Probe |
| CN1779688A (zh) | 2004-11-22 | 2006-05-31 | 寰硕数码股份有限公司 | 交互式医疗信息系统及方法 |
| EP1859050B1 (en) | 2005-03-18 | 2012-10-24 | The Chinese University Of Hong Kong | A method for the detection of chromosomal aneuploidies |
| EP1712639B1 (en) | 2005-04-06 | 2008-08-27 | Maurice Stroun | Method for the diagnosis of cancer by detecting circulating DNA and RNA |
| US20070122823A1 (en) | 2005-09-01 | 2007-05-31 | Bianchi Diana W | Amniotic fluid cell-free fetal DNA fragment size pattern for prenatal diagnosis |
| LT3002338T (lt) | 2006-02-02 | 2019-10-25 | Univ Leland Stanford Junior | Neinvazinė vaisiaus genetinė atranka, panaudojant skaitmeninę analizę |
| SI2351858T1 (sl) | 2006-02-28 | 2015-06-30 | University Of Louisville Research Foundation Med Center Three, | Zaznavanje fetalnih kromosomskih nenormalnosti z uporabo tandema polimorfizmov posameznih nukleotidov |
| EP2162534B1 (en) | 2007-05-24 | 2014-07-23 | Apceth GmbH & Co. KG | Genetically modified CD34 negative mesenchymal stem cells for tumour treatment |
| EP2557520B1 (en) * | 2007-07-23 | 2021-04-07 | The Chinese University of Hong Kong | Determining a nucleic acid sequence imbalance |
| US12180549B2 (en) | 2007-07-23 | 2024-12-31 | The Chinese University Of Hong Kong | Diagnosing fetal chromosomal aneuploidy using genomic sequencing |
| US20090053719A1 (en) | 2007-08-03 | 2009-02-26 | The Chinese University Of Hong Kong | Analysis of nucleic acids by digital pcr |
| KR20140107677A (ko) | 2007-09-19 | 2014-09-04 | 플루리스템 리미티드 | 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도 |
| WO2009051842A2 (en) | 2007-10-18 | 2009-04-23 | The Johns Hopkins University | Detection of cancer by measuring genomic copy number and strand length in cell-free dna |
| SI2562268T1 (sl) | 2008-09-20 | 2017-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel Building 170 | Neinvazivna diagnoza fetalne anevploidije s sekvenciranjem |
| WO2010053980A2 (en) † | 2008-11-04 | 2010-05-14 | The Johns Hopkins University | Dna integrity assay (dia) for cancer diagnostics, using confocal fluorescence spectroscopy |
| CN102369299A (zh) | 2009-03-31 | 2012-03-07 | 奥里迪斯生物标记有限责任公司 | 用于癌症诊断和癌症治疗监测的方法 |
| WO2011053790A2 (en) | 2009-10-30 | 2011-05-05 | Fluidigm Corporation | Assay of closely linked targets in fetal diagnosis and coincidence detection assay for genetic analysis |
| TWI458976B (zh) | 2009-11-05 | 2014-11-01 | Univ Hong Kong Chinese | 由母體之生物樣本分析胎兒之基因體 |
| EP2496713B1 (en) | 2009-11-06 | 2018-07-18 | The Chinese University of Hong Kong | Size-based genomic analysis |
| WO2011060240A1 (en) | 2009-11-12 | 2011-05-19 | Genzyme Corporation | Copy number analysis of genetic locus |
| AU2011207544A1 (en) | 2010-01-19 | 2012-09-06 | Verinata Health, Inc. | Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing |
| US10388403B2 (en) | 2010-01-19 | 2019-08-20 | Verinata Health, Inc. | Analyzing copy number variation in the detection of cancer |
| WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
| GB2479080B (en) | 2010-01-19 | 2012-01-18 | Verinata Health Inc | Sequencing methods and compositions for prenatal diagnoses |
| US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| US20130210645A1 (en) | 2010-02-18 | 2013-08-15 | The Johns Hopkins University | Personalized tumor biomarkers |
| CA2801468C (en) | 2010-06-04 | 2018-09-04 | Chronix Biomedical | Prostate cancer associated circulating nucleic acid biomarkers |
| EP2426217A1 (en) | 2010-09-03 | 2012-03-07 | Centre National de la Recherche Scientifique (CNRS) | Analytical methods for cell free nucleic acids and applications |
| TWI642786B (zh) | 2010-11-30 | 2018-12-01 | 香港中文大學 | 與癌症有關之基因或分子變異之檢測 |
| US20130059738A1 (en) | 2011-04-28 | 2013-03-07 | Life Technologies Corporation | Methods and compositions for multiplex pcr |
| US8712697B2 (en) | 2011-09-07 | 2014-04-29 | Ariosa Diagnostics, Inc. | Determination of copy number variations using binomial probability calculations |
| CA3069089A1 (en) | 2011-09-22 | 2013-03-28 | Lineage Biosciences, Inc. | Compositions and methods for analyzing heterogeneous samples |
| US10196681B2 (en) | 2011-10-06 | 2019-02-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| CA2850785C (en) | 2011-10-06 | 2022-12-13 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| WO2013060762A1 (en) | 2011-10-25 | 2013-05-02 | Roche Diagnostics Gmbh | Method for diagnosing a disease based on plasma-dna distribution |
| US9845552B2 (en) | 2011-10-27 | 2017-12-19 | Verinata Health, Inc. | Set membership testers for aligning nucleic acid samples |
| FR2981833B1 (fr) | 2011-10-28 | 2013-12-06 | Oreal | Sachet de conditionnement de produit cosmetique |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| WO2013086464A1 (en) | 2011-12-07 | 2013-06-13 | The Broad Institute, Inc. | Markers associated with chronic lymphocytic leukemia prognosis and progression |
| US9892230B2 (en) | 2012-03-08 | 2018-02-13 | The Chinese University Of Hong Kong | Size-based analysis of fetal or tumor DNA fraction in plasma |
| US20130261984A1 (en) | 2012-03-30 | 2013-10-03 | Illumina, Inc. | Methods and systems for determining fetal chromosomal abnormalities |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| US20150197785A1 (en) | 2012-08-10 | 2015-07-16 | The Broad Institute, Inc. | Methods and apparatus for analyzing and quantifying dna alterations in cancer |
| US20140066317A1 (en) | 2012-09-04 | 2014-03-06 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| CN110872617A (zh) | 2012-09-04 | 2020-03-10 | 夸登特健康公司 | 检测稀有突变和拷贝数变异的系统和方法 |
| US9769123B2 (en) | 2012-09-06 | 2017-09-19 | Intel Corporation | Mitigating unauthorized access to data traffic |
| DK3536807T3 (da) | 2012-09-20 | 2024-02-05 | Univ Hong Kong Chinese | Ikkeinvasiv bestemmelse af foster- eller tumormethylom fra plasma |
| US9732390B2 (en) | 2012-09-20 | 2017-08-15 | The Chinese University Of Hong Kong | Non-invasive determination of methylome of fetus or tumor from plasma |
| US20140287937A1 (en) | 2013-02-21 | 2014-09-25 | Toma Biosciences, Inc. | Methods for assessing cancer |
| CN105518151B (zh) | 2013-03-15 | 2021-05-25 | 莱兰斯坦福初级大学评议会 | 循环核酸肿瘤标志物的鉴别和用途 |
| EP2971097B1 (en) | 2013-03-15 | 2018-08-01 | Verinata Health, Inc | Generating cell-free dna libraries directly from blood |
| EP3036545B1 (en) | 2013-08-19 | 2019-07-03 | Singular Bio Inc. | Assays for single molecule detection and use thereof |
| US10262755B2 (en) | 2014-04-21 | 2019-04-16 | Natera, Inc. | Detecting cancer mutations and aneuploidy in chromosomal segments |
| EP4227947A1 (en) | 2013-10-21 | 2023-08-16 | Verinata Health, Inc. | Method for improving the sensitivity of detection in determining copy number variations |
| GB201319779D0 (en) | 2013-11-08 | 2013-12-25 | Cartagenia N V | Genetic analysis method |
| US10465238B2 (en) | 2013-12-19 | 2019-11-05 | The Board Of Trustees Of The Leland Stanford Junior University | Quantification of mutant alleles and copy number variation using digital PCR with nonspecific DNA-binding dyes |
| GB2524948A (en) | 2014-03-07 | 2015-10-14 | Oxford Gene Technology Operations Ltd | Detecting Increase or Decrease in the Amount of a Nucleic Acid having a Sequence of Interest |
| CN109971852A (zh) | 2014-04-21 | 2019-07-05 | 纳特拉公司 | 检测染色体片段中的突变和倍性 |
| ES2844229T3 (es) | 2014-05-13 | 2021-07-21 | Univ Texas | Mutaciones génicas y alteraciones en el número de copias de EGFR, KRAS y MET |
| BR112016027848A2 (pt) | 2014-05-30 | 2017-08-22 | Verinata Health Inc | Método para avaliação de número de cópias de uma sequência de interesse, meio legível por máquina não transitória, e, sistema para avaliação de número de cópias de uma sequência de interesse |
| MX2016016904A (es) | 2014-06-26 | 2017-03-27 | 10X Genomics Inc | Analisis de secuencias de acidos nucleicos. |
| TWI703216B (zh) | 2014-07-18 | 2020-09-01 | 香港中文大學 | Dna混合物中之組織甲基化模式分析 |
| CN107002122B (zh) | 2014-07-25 | 2023-09-19 | 华盛顿大学 | 确定导致无细胞dna的产生的组织和/或细胞类型的方法以及使用其鉴定疾病或紊乱的方法 |
| WO2016028316A1 (en) | 2014-08-22 | 2016-02-25 | Resolution Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| CN107075730A (zh) | 2014-09-12 | 2017-08-18 | 利兰·斯坦福青年大学托管委员会 | 循环核酸的鉴定及用途 |
| AU2015314114B2 (en) | 2014-09-12 | 2021-01-21 | Illumina Cambridge Limited | Detecting repeat expansions with short read sequencing data |
| EP3018213A1 (en) | 2014-11-04 | 2016-05-11 | Genesupport SA | Method for determining the presence of a biological condition by determining total and relative amounts of two different nucleic acids |
| CA2965528A1 (en) | 2014-11-14 | 2016-05-19 | Liquid Genomics, Inc. | Use of circulating cell-free rna for diagnosis and/or monitoring cancer |
| MA40939A (fr) | 2014-12-12 | 2017-10-18 | Verinata Health Inc | Utilisation de la taille de fragments d'adn acellulaire pour déterminer les variations du nombre de copies |
| US20170342500A1 (en) | 2014-12-19 | 2017-11-30 | Danmarks Tekniske Universitet | Method for identification of tissue or organ localization of a tumour |
| AU2015374259B2 (en) | 2014-12-31 | 2020-08-13 | Guardant Health, Inc. | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results |
| US10364467B2 (en) | 2015-01-13 | 2019-07-30 | The Chinese University Of Hong Kong | Using size and number aberrations in plasma DNA for detecting cancer |
| US10319463B2 (en) | 2015-01-23 | 2019-06-11 | The Chinese University Of Hong Kong | Combined size- and count-based analysis of maternal plasma for detection of fetal subchromosomal aberrations |
| EP4012715B1 (en) | 2015-02-10 | 2025-09-24 | The Chinese University Of Hong Kong | Detecting mutations for cancer screening and fetal analysis |
| EP3265079A4 (en) | 2015-03-03 | 2019-01-02 | Caris MPI, Inc. | Molecular profiling for cancer |
| CN114176582B (zh) | 2015-05-01 | 2024-09-17 | 夸登特健康公司 | 诊断方法 |
| ES2881977T3 (es) | 2015-05-06 | 2021-11-30 | Seracare Life Sciences Inc | Preparaciones liposomales para cribado no invasivo prenatal o de cáncer |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| US20180211002A1 (en) | 2015-07-13 | 2018-07-26 | Agilent Technologies Belgium Nv | System and methodology for the analysis of genomic data obtained from a subject |
| WO2017027391A2 (en) | 2015-08-07 | 2017-02-16 | Dana-Farber Cancer Institute, Inc. | Genetic abnormalities in plasma cell dyscrasias |
| US11756655B2 (en) | 2015-10-09 | 2023-09-12 | Guardant Health, Inc. | Population based treatment recommender using cell free DNA |
| WO2017070497A1 (en) | 2015-10-21 | 2017-04-27 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for use of driver mutations in cll |
| WO2017106768A1 (en) | 2015-12-17 | 2017-06-22 | Guardant Health, Inc. | Methods to determine tumor gene copy number by analysis of cell-free dna |
| US10982286B2 (en) | 2016-01-22 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine |
| WO2017205826A1 (en) | 2016-05-27 | 2017-11-30 | Sequenom, Inc. | Methods for detecting genetic variations |
| MY195527A (en) | 2016-10-24 | 2023-01-30 | Grail Inc | Methods And Systems For Tumor Detection |
-
2013
- 2013-03-07 US US13/789,553 patent/US9892230B2/en active Active
- 2013-03-08 RS RS20190946A patent/RS59073B1/sr unknown
- 2013-03-08 SI SI201331518T patent/SI3301193T1/sl unknown
- 2013-03-08 CN CN201710962960.XA patent/CN107630070B/zh active Active
- 2013-03-08 SM SM20190409T patent/SMT201900409T1/it unknown
- 2013-03-08 EP EP19201127.8A patent/EP3617324B1/en active Active
- 2013-03-08 CN CN201380013054.5A patent/CN104254618B/zh active Active
- 2013-03-08 PL PL17202838T patent/PL3301193T3/pl unknown
- 2013-03-08 ES ES17202838T patent/ES2729504T3/es active Active
- 2013-03-08 ES ES17209781T patent/ES2761624T3/es active Active
- 2013-03-08 AU AU2013229186A patent/AU2013229186B2/en active Active
- 2013-03-08 JP JP2014560451A patent/JP6073382B2/ja active Active
- 2013-03-08 WO PCT/IB2013/000312 patent/WO2013132305A1/en not_active Ceased
- 2013-03-08 ES ES13757943.9T patent/ES2659487T3/es active Active
- 2013-03-08 EP EP24159028.0A patent/EP4382613A3/en active Pending
- 2013-03-08 DK DK14193706.0T patent/DK2860266T3/en active
- 2013-03-08 PT PT17202838T patent/PT3301193T/pt unknown
- 2013-03-08 DK DK17209781.8T patent/DK3354748T3/da active
- 2013-03-08 EP EP19170660.5A patent/EP3575412B1/en active Active
- 2013-03-08 CA CA2865523A patent/CA2865523C/en active Active
- 2013-03-08 CN CN201710977855.3A patent/CN107630081B/zh active Active
- 2013-03-08 DK DK13757943.9T patent/DK2823062T5/en active
- 2013-03-08 EP EP14193706.0A patent/EP2860266B1/en active Active
- 2013-03-08 HU HUE17202838 patent/HUE044746T2/hu unknown
- 2013-03-08 EP EP13757943.9A patent/EP2823062B2/en active Active
- 2013-03-08 CA CA3010254A patent/CA3010254C/en active Active
- 2013-03-08 EP EP20209747.3A patent/EP3800272B1/en active Active
- 2013-03-08 EP EP21172741.7A patent/EP3882358B1/en active Active
- 2013-03-08 DK DK17202838.3T patent/DK3301193T3/da active
- 2013-03-08 LT LTEP17202838.3T patent/LT3301193T/lt unknown
- 2013-03-08 EP EP22190763.7A patent/EP4112740B1/en active Active
- 2013-03-08 EP EP17202838.3A patent/EP3301193B1/en active Active
- 2013-03-08 EP EP17209781.8A patent/EP3354748B1/en not_active Revoked
- 2013-03-08 DK DK19201127.8T patent/DK3617324T3/da active
-
2017
- 2017-01-04 JP JP2017000134A patent/JP6392904B2/ja active Active
- 2017-01-20 US US15/411,695 patent/US10741270B2/en active Active
- 2017-02-24 AU AU2017201258A patent/AU2017201258B2/en active Active
- 2017-05-05 US US15/587,662 patent/US10297342B2/en active Active
-
2018
- 2018-01-30 US US15/883,648 patent/US11217330B2/en active Active
- 2018-08-23 JP JP2018156137A patent/JP6721642B2/ja active Active
-
2019
- 2019-07-09 AU AU2019204917A patent/AU2019204917B2/en active Active
- 2019-07-18 HR HRP20191300TT patent/HRP20191300T1/hr unknown
- 2019-07-24 CY CY20191100784T patent/CY1121828T1/el unknown
-
2020
- 2020-06-18 JP JP2020105483A patent/JP6849257B2/ja active Active
- 2020-06-26 US US16/913,510 patent/US11031100B2/en active Active
-
2021
- 2021-02-25 JP JP2021028536A patent/JP7197209B2/ja active Active
- 2021-05-06 US US17/313,880 patent/US20210257053A1/en active Pending
- 2021-11-05 US US17/520,450 patent/US20220093212A1/en active Pending
-
2022
- 2022-05-17 AU AU2022203292A patent/AU2022203292A1/en not_active Abandoned
- 2022-12-08 JP JP2022196192A patent/JP2023017006A/ja active Pending
-
2024
- 2024-05-22 JP JP2024083480A patent/JP2024100931A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023017006A (ja) * | 2012-03-08 | 2023-02-02 | ザ チャイニーズ ユニバーシティー オブ ホンコン | Dnaのサイズに基づく解析 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7197209B2 (ja) | Dnaのサイズに基づく解析 | |
| HK40084570B (en) | Size-based analysis of fetal dna fraction in maternal plasma | |
| HK1245842B (zh) | 母体血浆中胎儿dna分数的基於大小的分析 | |
| HK1261405B (en) | Size-based analysis of dna for classification of cancer | |
| HK1246361B (zh) | 母体血浆中胎儿dna分数的基於大小的分析 | |
| HK1202135B (en) | Size-based analysis of fetal dna fraction in maternal plasma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150317 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150317 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160822 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161129 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170104 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6073382 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |